Look at the shift toward weekly at-home subcutaneous initiation for anti-amyloid Alzheimer's therapy and its implications for treatment delivery models.
Key Takeaways
- FDA approved a weekly subcutaneous starting dose enabling at-home administration
- Clinical data presented at AAIC showed similar performance and safety to IV initiation
- Previously patients had an 18-month IV initiation period before switching to maintenance dosing